Editas Medicine (EDIT) Other Non-Current Liabilities (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Other Non-Current Liabilities of $2.8 million for Q4 2025, down 8.37% year-over-year from $3.1 million in Q4 2024, and down 39.95% quarter-over-quarter from $4.7 million in Q3 2025.
Powered by 
Analysis
Editas Medicine (EDIT) Other Non-Current Liabilities (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Other Non-Current Liabilities for 9 consecutive years, with $2.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities fell 8.37% year-over-year to $2.8 million; the TTM figure through Dec 2025 stood at $2.8 million (down 8.37% YoY), while the FY2025 annual figure was $2.8 million, down 8.37% from the prior year.
- Other Non-Current Liabilities slipped to $2.8 million in Q4 2025 per EDIT's latest filing, from $4.7 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $6.4 million in Q1 2025 and bottomed at $1.8 million in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged $3.8 million across 3 years, with a median of $3.5 million in 2024.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 83.21% in 2025 and fell as far as 8.37% in 2025.
- Editas Medicine's Other Non-Current Liabilities stood at $1.8 million in 2023, then jumped by 70.67% to $3.1 million in 2024, then declined by 8.37% to $2.8 million in 2025.
- Business Quant data shows EDIT's Other Non-Current Liabilities at $2.8 million in Q4 2025, $4.7 million in Q3 2025, and $4.6 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.82 Mn |
| Sep 30, 2025 | 4.69 Mn |
| Jun 30, 2025 | 4.59 Mn |
| Mar 31, 2025 | 6.36 Mn |
| Dec 31, 2024 | 3.07 Mn |
| Sep 30, 2024 | 3.28 Mn |
| Jun 30, 2024 | 3.77 Mn |
| Mar 31, 2024 | 3.47 Mn |
| Dec 31, 2023 | 1.80 Mn |
| Dec 31, 2020 | 27.50 Mn |
| Mar 31, 2020 | 1,000.00 |
| Dec 31, 2019 | 1,000.00 |
| Sep 30, 2019 | 1,000.00 |
| Jun 30, 2019 | 1,000.00 |
| Mar 31, 2019 | 1,000.00 |
| Dec 31, 2018 | 293,000.00 |
| Sep 30, 2018 | 301,000.00 |
| Jun 30, 2018 | 305,000.00 |
| Mar 31, 2018 | 311,000.00 |
| Dec 31, 2017 | 317,000.00 |